Thank you very much. And thank you to everybody dialing in to listen to our comments and presentation of the Q1 report here in our fiscal year 2024. I have our CFO, Magnus Blixt, with me, and we're happy to share all the insights that we just published this morning. So we can go to the first slide where we talk about the quarter in brief. For Q3, we designated the title of the report as 'Strong Sales in EMEA Amid Market Uncertainty.' So I would say the quarter has been characterized by a reasonable Q3. Also historically, it's not our strongest quarter. However, the fluctuations among the different regions are distinct. We have seen EMEA really benefit from very strong growth across multiple markets, but also across essentially all product groups. Um, and then we are up against a weak comparable, a favorable comparison to last year. Sales have declined in the Americas. We've seen uncertainties play out in the clinical settings around the hospital environment. Delays in both tendering and order placement have occurred, given the political situation surrounding the election which has been the main driver for the uncertainty and not securing sufficient orders. This is what we see as a temporary thing in the market and not a sign of competitive changes in APAC. We see fluctuations during quarters. And here we would say we've had three strong quarters shipping to China, and this time around, no shipments there, but actually strong shipments elsewhere. So, it's in our book. It's purely fluctuations amongst quarters when we comment on APAC specifically, that gives us an organic growth of 9% this quarter, almost double digit, and it translates into an EBITDA of 27 percentage points. In terms of revenue, I can highlight that the actual revenue is 179 million, compared to 168 million last year. Um, in terms of progress on our strategic direction. And then, uh, we've been, you can say, transitioning into a strategic partnership alliance with Sysmex earlier in the year. So, we've been working with multiple markets and really getting to know them and the market specifics. And I'm proud to say that we are continuing that journey on both a tactical and an educational level. So here we've really paved the way for joint training and marketing activities, and how we share and conduct e-learning across all countries in a global setting. So, I think we've accomplished quite a bit together there. And this will be the fruit going forward of educating the community in digital dermatology via some of these tools. Furthermore, on the development side, we have started our clinical validation. We completed the pre-clinical validation of our bone marrow earlier this year. And now we are actually in the midst of executing our regulatory and clinical validation leading to the regulatory process in 2025. So we are active in two European sites and soon in a US site with our bone marrow validation. And so we are still aiming to launch the bone marrow with the CE mark for Europe in 2025. So that's according to the plan.
And if we proceed and try to unfold the P&L that we reported and set on this slide, you'll see it's a little bit busy. We have the quarter. We are just reporting on the very left-hand side, and then we have the comparable quarter, followed by the year-to-date and the full year last year. So in the first column here, 179 million assets, giving us a 9% growth organically. When we correct for the FX impacts, we have three negative percentage points in FX that we absorbed under the gross margin. And furthermore, we are seeing an increase from 66 to 68% in the gross margin.
And that is what we have alluded to previously, that the kick in of the majority of the price increases takes place right now, and this is what we've been able to demonstrate by the increase here of a couple of percentage points. So that has been according to our expectations. On the operating expense side, we are seeing a slight decline in sales, despite, of course, the normal annual adjustments, etc. . And that refers to the restructuring we undertook last year. And then we are spending a little bit more on the admin side in terms of consultants to get ready for regulatory requirements coming up. In the upcoming years. And then according to plan, we are investing a little bit more in R&D. Given the maturity of our pipeline and our development programs. And that brings us to an EBITDA of 47 million. . Sorry, 49 million, equivalent to 27%. So in essence, it's 22% of R&D as a percentage of sales this quarter. And then we are capitalizing for $14 million in this quarter. Cash flow-wise, still a strong cash flow. But obviously on paper here it looks much weaker than the comparable quarter. That is really working capital. There are two drivers for this. Since we have a difference of 40 million in accounts receivable compared to the comparable quarter. We have not changed any terms. We have an unchanged aging profile, etc. So it's really about when we receive the actual monies that were outside of the quarter. So that's kind of like that's replacing, if you like. And then inventory. We're up against last year where we had some weak quarters, and then we really gained on clearing our inventory or cutting down on the inventory level, which was really cash flow positive. We have not done that to the same extent this quarter. This is also part of the story when we unfold the differences here. Having said that, we've continued to decrease the inventory level quarter by quarter.
Um, so we're on a good track there. And that gives us a total cash flow of 16 million during this quarter. All right. So let's go to the regional highlights. Yeah. So negative growth of 20% in Q3. So this is really the big hit. And we really attribute this to the uncertainty surrounding the political climate around the election. This is something we've also explored at seminars and elsewhere, and of course in dialogue with our customers. So we are really seeing a hesitation at the hospitals to actually place the investment in capital equipment. Um, so the interest rate, the uncertainty around the interest rate, and potentially budgets, that is the underlying driver for that pattern, which apparently was also part of the equation four years ago, even though we were just disturbed by the pandemic at the time. I mean, as I said, very favorable growth across markets, different markets, across the product lines. We also disclosed that we had a couple of orders on top in September, and that was really to preempt logistical disruptions later in the year for one of our partners. However, even we felt that there was a need to be super transparent about it because, yes, that does elevate our position somewhat. But if we reduce even with our estimate of that, then we would still be at an all-time high in sales in India. So, I think we can faithfully say that we have good momentum across multiple markets. Um, and I think, yeah, I'll get back to the reagents and APAC. As I said, we have seen fluctuations across quarters and lately, we've actually gained momentum. The tricky thing when I mention China is that sometimes, when we serve China, it involves a large volume of orders. We ship at once. So whether they are in a quarter or not, that really influences our numbers. Now, we've had three quarters with shipments going to China. So, and this time around, this did not take place. That's really a function of all the distributors serving the hospital market in China. Whether our partner is placing an order or not. And that was not the case. However, we are seeing a lot of significant activities across APAC, both in Japan and this time around Singapore, and we have had a lot of good intentions and fruitful dialogue around Australia-New Zealand as well.
So we would describe the soft quarter of 12 million versus 22 as a facing and a facing component. If we examine the numbers by product group, instrument sales were at 6%. And obviously, 6% is a little bit on the low side. Also, given the fact that it's large instruments that drive the majority of our revenue. And so we're a little bit impacted, especially from the US piece. But again, both large instruments and other strong instruments were actually significant across Europe. And so, we like to see that this trend is continuing because we've actually had quite a number of quarters where this took place in EMEA, reagent-wise. Here I would highlight that we have 11% growth. We have 12% in EMEA. Uh, and that is a combination of both hematology reagents and non-hematology reagents. So we are continuing a steady double-digit growth in the reagent market. Software wise, it's a little bit soft. And that is also a function since it follows the instrument sales. Um, the instrument sales. However, we are. Just like I said, across EMEA, we are also seeing software as a positive contributor to revenue growth. Let's just jump into the key takeaways. Yes, the concise version is that we are indeed observing strong growth. We continue to see growth across multiple markets and product groups. In EMEA we have seen this delay which takes place as we speak in the US. So we are trying to follow that as closely as we can and assess what the implications are from other companies. But this is really our conclusion that we did see the political uncertainty as a wait-and-see component. As mentioned, there is fluctuation in APAC. We have good belief that we have traction in multiple markets out there. And then we have really found a way to deploy our training modules in a digital fashion and share that across multiple markets, in fact, globally. And so that has been a major milestone on the internal lines, which will hit and serve the customers in how they deploy digital morphology, how they understand digital cell morphology, and how they deploy our solutions to serve that need. It's great progress according to plan, with clinical validations being executed in two sites soon. Three. So we are driving the plan accordingly there. So with that, I think we should invite the audience to pose any questions you may have. We would be happy to answer those. So thank you very much for your attention.